The current stock price of ANIP is 82.99 USD. In the past month the price increased by 2.8%. In the past year, price increased by 41.52%.
ChartMill assigns a technical rating of 3 / 10 to ANIP. When comparing the yearly performance of all stocks, ANIP is one of the better performing stocks in the market, outperforming 77.14% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to ANIP. Both the profitability and the financial health of ANIP get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months ANIP reported a non-GAAP Earnings per Share(EPS) of 7.17. The EPS increased by 56.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.13% | ||
| ROA | 2.42% | ||
| ROE | 6.75% | ||
| Debt/Equity | 1.2 |
14 analysts have analysed ANIP and the average price target is 110.6 USD. This implies a price increase of 33.27% is expected in the next year compared to the current price of 82.99.
For the next year, analysts expect an EPS growth of 48.17% and a revenue growth 45.11% for ANIP
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
ANI PHARMACEUTICALS INC
210 Main Street West
Baudette MINNESOTA 56623 US
CEO: Nikhil Lalwani
Employees: 897
Phone: 12186343500
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 897 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
The current stock price of ANIP is 82.99 USD. The price decreased by -2.81% in the last trading session.
ANIP does not pay a dividend.
ANIP has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
ANIP stock is listed on the Nasdaq exchange.
ANI PHARMACEUTICALS INC (ANIP) has a market capitalization of 1.86B USD. This makes ANIP a Small Cap stock.
You can find the ownership structure of ANI PHARMACEUTICALS INC (ANIP) on the Ownership tab.